Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) shot up 1.8% on Monday . The stock traded as high as $5.75 and last traded at $5.75. 300 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 10,019 shares. The stock had previously closed at $5.65.
Idorsia Price Performance
The company has a fifty day simple moving average of $4.91 and a two-hundred day simple moving average of $4.69.
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Further Reading
- Five stocks we like better than Idorsia
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
